20:05 , Dec 7, 2018 |  BC Week In Review  |  Clinical News

Aprea's MDS candidate leads to 95% ORR in Phase Ib/II

Aprea Therapeutics AB (Stockholm, Sweden) reported data from 20 evaluable patients with myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) in a Phase Ib/II trial showing that APR-246 plus Vidaza azacitidine led to an overall...
18:14 , Dec 7, 2018 |  BC Week In Review  |  Financial News

Aprea heading for Phase III with €50M series C round

Aprea Therapeutics AB (Solna, Sweden) raised €50 million ($56.9 million) in a series C round on Nov. 30, with which it intends to fund a Phase III study of lead candidate APR-246 to treat myelodysplastic...
19:23 , Nov 30, 2018 |  BC Extra  |  Financial News

Aprea heading for Phase III with €50M series C round

Aprea Therapeutics AB (Solna, Sweden) raised €50 million ($56.9 million) in a series C round, with which it intends to fund a Phase III study of lead candidate APR-246 to treat myelodysplastic syndrome (MDS). The...
19:49 , Apr 27, 2018 |  BC Week In Review  |  Clinical News

Aprea reports Phase Ib/II response data for APR-246 in MDS

Aprea Therapeutics AB (Stockholm, Sweden) said APR-246 plus Vidaza azacitidine led to an overall response rate (ORR) of 100%, including six complete responses and two marrow complete responses, in eight evaluable patients with myelodysplastic syndrome...
23:34 , Nov 2, 2017 |  BC Innovations  |  Targets & Mechanisms

Golden State of DUBs

Four papers in the last two weeks describing inhibitors of the ubiquitin-regulating protein USP7 could signal an important breakthrough in the ability to drug DUBs, a class of enzymes that has been stubbornly intractable until...
19:51 , May 25, 2017 |  BC Week In Review  |  Clinical News

Aprea starts Phase Ib/II of APR-246 for MDS

Aprea Therapeutics AB (Solna, Sweden) began an open-label, U.S. Phase Ib/II trial to evaluate APR-246 in about 60 patients with tumor protein p53 ( TP53 ; p53) mutant myelodysplastic syndrome (MDS). The dose-escalation Phase I...
17:15 , Apr 13, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Esophageal cancer; cancer Cell culture and mouse studies suggest SLC7A11 inhibitors could help treat p53 -mutant esophageal cancer and other cancers that are resistant to p53 activators. In 10 p53-mutant esophageal cancer cell lines,...
19:12 , Dec 15, 2016 |  BC Innovations  |  Product R&D

p53 and Ras: Back from the dead

After decades of research and countless failed attempts at drug development, industry is reviving its interest in two of oncology’s most intractable targets, p53 and Ras. While no one denies there’s still a long road...
17:34 , Nov 4, 2016 |  BC Week In Review  |  Clinical News

APR-246: Additional Ph Ib data

Additional data from 22 evaluable patients with platinum-sensitive, high-grade serous ovarian cancer in the Phase Ib portion of the international Phase Ib/II PiSARRO trial showed that second-line treatment with IV APR-246 plus carboplatin and pegylated...
07:00 , Aug 22, 2016 |  BioCentury  |  Finance

Northern Lights 2.0

A sea change is taking place in the Scandinavian biotech ecosystem, as an uptick in acquisitions and international investor syndicates shows science coming out of the region's academic institutes is increasingly able to find a...